XML 31 R23.htm IDEA: XBRL DOCUMENT v3.22.1
CAPITAL STOCK (Details Narrative)
12 Months Ended
Dec. 28, 2021
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Common Stock, Shares Authorized   480,000,000 480,000,000
Common Stock, Par or Stated Value Per Share | $ / shares   $ 0.001 $ 0.001
Preferred Stock, Shares Authorized   20,000,000 20,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares   $ 0.001  
Common Stock, Shares, Issued   50,634,536 50,605,965
Preferred Stock, Shares Issued   0 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number   9,950,000  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate   2.88%  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term   5 years  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate   195.37%  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate   0.00%  
Stock Option 1 [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | $ / shares   $ 0.06  
Share Price | $ / shares   $ 0.095  
Stock Option 2 [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number   9,500,000  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | $ / shares   $ 0.06  
Share Price | $ / shares   $ 0.095  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | $   $ 332,500 $ 760,000
Series A Preferred Stock [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Preferred Stock, Shares Authorized   1,000,000 1,000,000
Sapir Pharmaceuticals Inc [Member] | Series A Preferred Stock [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 1,000,000    
Preferred Stock, Convertible, Conversion Ratio 450    
Common Stock [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   28,571